The treatment, developed by researchers from UCLA and the U.K., has restored immune function in more than 95% of patients in three clinical trials.
A UCLA study identifies a cell therapy that can stop progressive damage and stimulate the brain’s repair processes in mice.
Research brief: A UCLA team has demonstrated that altering a key molecule used in the therapy yields superior and longer-lasting results in mouse models.
The project is the first to use the Nobel prize–winning technology to directly correct sickle mutation in blood stem cells.
Professors Robert Damoiseaux and Vaithilingaraja Arumugaswami led a collaboration among scientists from the U.S. and Germany.
The advance could be a step toward the development of treatments for muscle loss or damage due to injury, age or disease.
UCLA’s Dr. Arjun Deb said the same model could also help researchers learn more about other similar viruses that might emerge in the future.
“It’s too early to declare victory, but it’s looking quite promising at this point,” said UCLA’s Dr. Donald Kohn.
Researchers used a model of airway tissue created from human stem cells to understand the process on cellular level.
The advance will enable scientists to follow the precise path by which T cells are formed from blood stem cells inside the thymus.
UCLA testing found that AMBMP allowed mouse muscles to work and grow the way healthy muscle cells do.
Broad Stem Cell Research Center investigators are are channeling their specialized expertise to fight the novel coronavirus.
A UCLA study sheds light on how aging can cause lung regeneration to go awry, which can lead to lung cancer and other diseases.
Two members of the UCLA Broad Stem Cell Research Center have received a grant for work that could be helpful in developing a vaccine.
Researchers will focus on an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy the virus.
The findings are critical for researchers aiming to develop muscle stem cells in the lab that can be used to combat disease.
The findings could eventually lead to new drugs to treat or prevent lung cancer.
UCLA-led research uncovers new details about the Foxp1 gene, which also is involved in timing of neuron production.
UCLA researchers were part of an international team to test gene therapy in people with X-linked chronic granulomatous disease.
The advance could help scientists identify drugs to treat fibrosis, which plays a role in chronic kidney disease, liver cirrhosis and many other conditions.
Research brief: The new method, using robotics, will speed up how researchers test for therapies that block the metabolism of non-small-cell lung cancer tumors.
The finding could lead to better treatments for leukemia and other blood diseases.
Funds from California’s stem cell agency will support research on a blinding eye disease, cancer and an immune disorder.
The study, conducted in mice, is the first to show that creatine uptake is critical to the anti-tumor activities of what is known as killer T cells, the foot soldiers of the immune system.
Findings of the research conducted in mice could inform the development of therapies that reduce the time it takes for people to recover from nerve injuries.